Molly Fensterwald, Jordan Johnson, Angel Moreno, Shawn Conger-Love, Charles Flippen, Chelsea Hesterman, Mollie Johnston, Joshua Kamins, Karla Minota, Peony Pak, Salman Hashim, Thanh-Liem Huynh-Tran, Noelle Kobayashi, Bradley Shane, Andrew Charles, Sinifunanya Nwaobi
Suzetrigine is a selective voltage-gated sodium channel blocker that was recently approved by the US Food and Drug Administration for the treatment of acute pain. We retrospectively evaluated the efficacy and tolerability of suzetrigine for the treatment of different headache disorders in patients refractory to standard treatments in an academic headache center. These patients had a variety of headache and facial pain diagnoses, including chronic migraine, medication-overuse headache, trigeminal autonomic cephalalgias, nummular headache, occipital neuralgia, and persistent idiopathic facial pain. Some did not clearly meet any diagnostic criteria. The treatment was generally well tolerated, and most patients reported improvement as measured by patient global impression of change. Suzetrigine is a promising new therapeutic approach that warrants further study for the treatment of headache disorders.